Sugi Predict

Sugi Predict / Compounds / SCHEMBL3208404

SCHEMBL3208404

SCHEMBL3208404

COCCOc1ccc(C=CC(=O)O)c(OCc2ccccc2)c1

nearest known ligand 0.64

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ HDAC8 Q9BY41 3/20 0.64
▸ PTGER3 P43115 6/20 0.58
▸ PTGER4 P35408 6/20 0.58
▸ PTGER2 P43116 6/20 0.58
▸ PTGER1 P34995 4/20 0.58
▸ PLA2G2D Q9UNK4 1/20 0.53
▸ PTGDR Q13258 1/20 0.52
▸ KDM4E B2RXH2 2/20 0.51
▸ ALDH1A1 P00352 1/20 0.51
▸ PKM P14618 1/20 0.51
▸ APP P05067 1/20 0.50
▸ MAPT P10636 1/20 0.50
▸ LMNA P02545 1/20 0.49
▸ LTB4R Q15722 1/20 0.47
▸ LTB4R2 Q9NPC1 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3208391 1.00 HDAC8 (0.64) HDAC8PTGER3PTGER4PTGER2PTGER1
SCHEMBL5119417 0.89 HDAC8 (0.61) HDAC8PTGER3PTGER4PTGER2PTGER1
SCHEMBL3218772 0.89 HDAC8 (0.65) HDAC8PTGER3PTGER4PTGER2PTGER1
SCHEMBL5119409 0.89 HDAC8 (0.61) HDAC8PTGER3PTGER4PTGER2PTGER1
SCHEMBL3218760 0.89 HDAC8 (0.65) HDAC8PTGER3PTGER4PTGER2PTGER1
SCHEMBL7191225 0.89 PTGER3 (0.68) HDAC8PTGER3PTGER4PTGER2PTGER1
SCHEMBL7909151 0.89 PTGER3 (0.68) HDAC8PTGER3PTGER4PTGER2PTGER1
SCHEMBL27716287 0.88 HDAC8 (0.64) HDAC8PTGER3PTGER4PTGER2PTGER1
SCHEMBL6035015 0.88 HDAC8 (0.80) HDAC8PTGER3PTGER4PTGER2PTGER1
SCHEMBL6035013 0.88 HDAC8 (0.80) HDAC8PTGER3PTGER4PTGER2PTGER1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100041892-A1 Therapeutic agent for diabetes ABE HIDENORI 2010-02-18 — — US disclosed
US-20090270631-A1 Therapeutic agent for diabetes ABE HIDENORI 2009-10-29 — — US disclosed
EP-1912645-A2 THERAPEUTIC AGENT FOR DIABETES Takeda Pharmaceutical Company Limited (JP) 2008-04-23 — — EP disclosed
US-20080051418-A1 Arylalkanoic Acid Derivative TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-02-28 — — US disclosed
US-20080009530-A1 Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-10 — — US disclosed
EP-1829863-A1 ARYLALKANOIC ACID DERIVATIVE Takeda Pharmaceutical Company Limited (JP) 2007-09-05 — — EP disclosed
WO-2007018314-A2 THERAPEUTIC AGENT FOR DIABETES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-02-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270631-A1 Therapeutic agent for diabetes FABP4, SLC5A1, SLC5A2 HDAC8 789/4885PTGER3 2459/4885PTGER4 2014/4885
US-20080051418-A1 Arylalkanoic Acid Derivative INSR, NPY1R, GPR119 HDAC8 156/4885PTGER3 1565/4885PTGER4 1928/4885
US-20080009530-A1 Therapeutic Agent for Diabetes FABP4, SLC5A1, SLC5A2 HDAC8 663/4885PTGER3 2522/4885PTGER4 2098/4885
US-20100041892-A1 Therapeutic agent for diabetes FABP4, SLC5A1, SLC5A2 HDAC8 789/4885PTGER3 2459/4885PTGER4 2014/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.